This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Idexx Laboratories (IDXX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.
IDEXX Launches Cytology Service to Upgrade Veterinary Care
by Zacks Equity Research
IDEXX (IDXX) upgrades veterinary care experience by launching a rapid digital cytology service, thus enabling the provision of faster results.
S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF
by Sanghamitra Saha
The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.
Top-Ranked Nasdaq-100 ETF at New High: 5 Best Stocks
by Sanghamitra Saha
Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.
IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View
by Zacks Equity Research
IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.
Idexx Laboratories (IDXX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 9.73% and 1.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Impressive Near-Term Outlook for Medical Instruments Industry
by Urmimala Biswas
Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.
Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More
by Urmimala Biswas
Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?
by Zacks Equity Research
Growth in Rapid Assays and Veterinary Software revenues is expected to get reflected in IDEXX's (IDXX) third-quarter results.
Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX's (IDXX) performance.
IDEXX's Kidney Function Test Included in IRIS Staging Views
by Zacks Equity Research
IDEXX (IDXX) is upbeat about the inclusion and approval of the SDMA-based renal care staging guidelines.
Idexx (IDXX) Up 8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on IDEXX Laboratories' (IDXX) prospects.
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
by Zacks Equity Research
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
IDEXX (IDXX) Beats Q2 Earnings Estimates, Lifts EPS Guidance
by Zacks Equity Research
IDEXX's (IDXX) top line in the second quarter gains from strong sales at the CAG business.
Idexx Laboratories (IDXX) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 4.38% and -1.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?
by Zacks Equity Research
In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Idexx (IDXX)
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS
4 Stocks to Make the Most of the Growing Love for Pets
by Tirthankar Chakraborty
With the U.S. pet industry poised to grow 3.9% to a record $75.4 billion this year, here are few stocks that could gain from the growing love for animals.
IDEXX (IDXX) Gains Traction From Solid CAG, Global Strength
by Zacks Equity Research
IDEXX (IDXX) consistently benefits from strong organic growth, driven by robust sales at the CAG business, fueled by a firm global Catalyst adoption.
Near-Term Outlook for Medical Instruments Industry Bleak
by Urmimala Biswas
Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.